Home・Stock List・Sana Biotechnology Inc

Sana Biotechnology Inc

Closed

SectorHealthcare

3.81 4.96

Buy Sell

Overview

Share price change

24h

Current

Min

3.5300000000000002

Max

3.8

Key metrics
By Trading Economics
Income	-16M -64M
EPS	-0.13
Employees	142
EBITDA	-21M -65M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+128.53% upside

Dividends
By Acuity
Next Earnings	14 Aug 2026

Market Stats
By TradingEconomics
Market Cap	120M 1B
Previous open	-1.15
Previous close	3.81

News Sentiment

By Acuity

25%

75%

49 / 340 Healthcare

Sana Biotechnology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Aug 2026, 19:31 UTC

News

Sana Biotechnology shares are higher following Q2 results showing an adjusted EPS of -$0.13, exceeding estimates, and a $25 million investment from Mayo Clinic.

10 Aug 2026, 23:01 UTC

News

Sana Biotechnology Inc shares are lower in after-market hours following a second-quarter loss of $63.6 million, despite an adjusted EPS that exceeded expectations.

7 Aug 2026, 19:56 UTC

Sana Biotechnology Inc. shares are higher, supported by broader market dynamics following a disappointing jobs report easing interest rate concerns.

5 Aug 2026, 19:56 UTC

Sana Biotechnology Inc. is trading higher during Wednesday's session, having peaked earlier before pulling back slightly while remaining above its 20-day moving average.

4 Aug 2026, 20:05 UTC

Sana Biotechnology Inc shares are higher, reflecting strong performance amid a decline in crude oil prices, which may ease inflationary pressures.

3 Aug 2026, 19:46 UTC

Sana Biotechnology Inc is higher today, benefiting from a broader market rally, particularly in technology, despite earlier session pullbacks.

31 Jul 2026, 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, retracing from earlier gains. Broader market trends show mixed sentiment among major tech firms.

30 Jul 2026, 19:29 UTC

Sana Biotechnology Inc shares are higher today, recovering from earlier lows. The stock has shown an upward trend since Wednesday's close.

29 Jul 2026, 23:36 UTC

Sana Biotechnology Inc shares are higher in after-market hours, reflecting a slight increase since Wednesday's close amid routine market activity and broader volatility.

28 Jul 2026, 18:03 UTC

Sana Biotechnology Inc. shares are higher as biotechnology stocks advance, though they diverge from a recent trend of daily gains since Monday's close.

27 Jul 2026, 19:07 UTC

Sana Biotechnology Inc shares are higher today, continuing a rally since Friday. No specific news has been identified to explain the price movement.

24 Jul 2026, 18:26 UTC

Sana Biotechnology Inc. shares are trading lower amid broader market volatility, with no specific company news identified to explain the decline.

22 Jul 2026, 19:36 UTC

News

Sana Biotechnology has shifted focus to B-cell autoimmune disorders amid competition in oncology. Shares are higher since Tuesday, supported by rising crude oil prices.

20 Jul 2026, 17:56 UTC

Social Media

Sana Biotechnology Inc shares are lower, continuing a nine-session decline. Social media discussions raise skepticism about the timeline for its allogeneic cell therapies.

Peer Comparison

Price change

Sana Biotechnology Inc Forecast

Price Target

By TipRanks

128.53% upside

12 Months Forecast

Average 8.25 USD 128.53%

High 12 USD

Low 7 USD

Based on 4 Wall Street analysts offering 12 month price targets forSana Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Sana Biotechnology Inc - Dist in the past 3 months.

Sentiment

By Acuity

49 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.